Literature DB >> 22198154

Mice heterozygous for CREB binding protein are hypersensitive to γ-radiation and invariably develop myelodysplastic/myeloproliferative neoplasm.

Stephanie N Zimmer1, Madeleine E Lemieux, Bijal P Karia, Claudia Day, Ting Zhou, Qing Zhou, Andrew L Kung, Uthra Suresh, Yidong Chen, Marsha C Kinney, Alexander J R Bishop, Vivienne I Rebel.   

Abstract

Myelodysplastic syndrome is a complex family of preleukemic diseases in which hematopoietic stem cell defects lead to abnormal differentiation in one or more blood lineages. Disease progression is associated with increasing genomic instability and a large proportion of patients go on to develop acute myeloid leukemia. Primarily a disease of the elderly, it can also develop after chemotherapy. We have previously reported that CREB binding protein (Crebbp) heterozygous mice have an increased incidence of hematological malignancies, and others have shown that CREBBP is one of the genes altered by chromosomal translocations found in patients suffering from therapy-related myelodysplastic syndrome. This led us to investigate whether hematopoietic tumor development in Crebbp(+/-) mice is preceded by a myelodysplastic phase and whether we could uncover molecular mechanisms that might contribute to its development. We report here that Crebbp(+/-) mice invariably develop myelodysplastic/myeloproliferative neoplasm within 9 to 12 months of age. They are also hypersensitive to ionizing radiation and show a marked decrease in poly(ADP-ribose) polymerase-1 activity after irradiation. In addition, protein levels of XRCC1 and APEX1, key components of base excision repair machinery, are reduced in unirradiated Crebbp(+/-) cells or upon targeted knockdown of CREBBP levels. Our results provide validation of a novel myelodysplastic/myeloproliferative neoplasm mouse model and, more importantly, point to defective repair of DNA damage as a contributing factor to the pathogenesis of this currently incurable disease. Copyright Â
© 2012 ISEH - Society for Hematology and Stem Cells. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22198154      PMCID: PMC3402047          DOI: 10.1016/j.exphem.2011.12.004

Source DB:  PubMed          Journal:  Exp Hematol        ISSN: 0301-472X            Impact factor:   3.084


  41 in total

Review 1.  Target gene context influences the transcriptional requirement for the KAT3 family of CBP and p300 histone acetyltransferases.

Authors:  David C Bedford; Lawryn H Kasper; Tomofusa Fukuyama; Paul K Brindle
Journal:  Epigenetics       Date:  2010-01-27       Impact factor: 4.528

2.  Integration of biological networks and gene expression data using Cytoscape.

Authors:  Melissa S Cline; Michael Smoot; Ethan Cerami; Allan Kuchinsky; Nerius Landys; Chris Workman; Rowan Christmas; Iliana Avila-Campilo; Michael Creech; Benjamin Gross; Kristina Hanspers; Ruth Isserlin; Ryan Kelley; Sarah Killcoyne; Samad Lotia; Steven Maere; John Morris; Keiichiro Ono; Vuk Pavlovic; Alexander R Pico; Aditya Vailaya; Peng-Liang Wang; Annette Adler; Bruce R Conklin; Leroy Hood; Martin Kuiper; Chris Sander; Ilya Schmulevich; Benno Schwikowski; Guy J Warner; Trey Ideker; Gary D Bader
Journal:  Nat Protoc       Date:  2007       Impact factor: 13.491

Review 3.  Mouse models of myelodysplastic syndromes.

Authors:  Sarah H Beachy; Peter D Aplan
Journal:  Hematol Oncol Clin North Am       Date:  2010-04       Impact factor: 3.722

Review 4.  The PARP side of the nucleus: molecular actions, physiological outcomes, and clinical targets.

Authors:  Raga Krishnakumar; W Lee Kraus
Journal:  Mol Cell       Date:  2010-07-09       Impact factor: 17.970

Review 5.  The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes.

Authors:  James W Vardiman; Jüergen Thiele; Daniel A Arber; Richard D Brunning; Michael J Borowitz; Anna Porwit; Nancy Lee Harris; Michelle M Le Beau; Eva Hellström-Lindberg; Ayalew Tefferi; Clara D Bloomfield
Journal:  Blood       Date:  2009-04-08       Impact factor: 22.113

Review 6.  Therapy-related myeloid leukemia.

Authors:  Lucy A Godley; Richard A Larson
Journal:  Semin Oncol       Date:  2008-08       Impact factor: 4.929

7.  Oxidative DNA damage in bone marrow cells of patients with low-risk myelodysplastic syndrome.

Authors:  Bozena Novotna; Yana Bagryantseva; Magda Siskova; Radana Neuwirtova
Journal:  Leuk Res       Date:  2008-08-08       Impact factor: 3.156

8.  JAK2 stimulates homologous recombination and genetic instability: potential implication in the heterogeneity of myeloproliferative disorders.

Authors:  Isabelle Plo; Mayuka Nakatake; Laurent Malivert; Jean-Pierre de Villartay; Stéphane Giraudier; Jean-Luc Villeval; Lisa Wiesmuller; William Vainchenker
Journal:  Blood       Date:  2008-05-30       Impact factor: 22.113

9.  Base excision repair dysfunction in a subgroup of patients with myelodysplastic syndrome.

Authors:  A M Jankowska; L P Gondek; H Szpurka; Z P Nearman; R V Tiu; J P Maciejewski
Journal:  Leukemia       Date:  2007-12-06       Impact factor: 11.528

10.  Broad network-based predictability of Saccharomyces cerevisiae gene loss-of-function phenotypes.

Authors:  Kriston L McGary; Insuk Lee; Edward M Marcotte
Journal:  Genome Biol       Date:  2007       Impact factor: 13.583

View more
  14 in total

Review 1.  CREBBP and p300 lysine acetyl transferases in the DNA damage response.

Authors:  Ilaria Dutto; Claudia Scalera; Ennio Prosperi
Journal:  Cell Mol Life Sci       Date:  2017-11-23       Impact factor: 9.261

Review 2.  Revisiting the case for genetically engineered mouse models in human myelodysplastic syndrome research.

Authors:  Ting Zhou; Marsha C Kinney; Linda M Scott; Sandra S Zinkel; Vivienne I Rebel
Journal:  Blood       Date:  2015-06-15       Impact factor: 22.113

Review 3.  cAMP Signaling in Cancer: A PKA-CREB and EPAC-Centric Approach.

Authors:  Muhammad Bilal Ahmed; Abdullah A A Alghamdi; Salman Ul Islam; Joon-Seok Lee; Young-Sup Lee
Journal:  Cells       Date:  2022-06-24       Impact factor: 7.666

Review 4.  Myelodysplastic syndrome: an inability to appropriately respond to damaged DNA?

Authors:  Ting Zhou; Paul Hasty; Christi A Walter; Alexander J R Bishop; Linda M Scott; Vivienne I Rebel
Journal:  Exp Hematol       Date:  2013-04-30       Impact factor: 3.084

5.  Cells deficient in base-excision repair reveal cancer hallmarks originating from adjustments to genetic instability.

Authors:  Enni Markkanen; Roman Fischer; Marina Ledentcova; Benedikt M Kessler; Grigory L Dianov
Journal:  Nucleic Acids Res       Date:  2015-03-23       Impact factor: 16.971

Review 6.  KATs in cancer: functions and therapies.

Authors:  A Farria; W Li; S Y R Dent
Journal:  Oncogene       Date:  2015-02-09       Impact factor: 9.867

7.  CREBBP is a target of epigenetic, but not genetic, modification in juvenile myelomonocytic leukemia.

Authors:  Christoph Plass; Christian Flotho; Silvia Fluhr; Melanie Boerries; Hauke Busch; Aikaterini Symeonidi; Tania Witte; Daniel B Lipka; Oliver Mücke; Peter Nöllke; Christopher Felix Krombholz; Charlotte M Niemeyer
Journal:  Clin Epigenetics       Date:  2016-05-05       Impact factor: 6.551

Review 8.  Control of CREB expression in tumors: from molecular mechanisms and signal transduction pathways to therapeutic target.

Authors:  André Steven; Barbara Seliger
Journal:  Oncotarget       Date:  2016-06-07

Review 9.  Regulation of Cancer Cell Responsiveness to Ionizing Radiation Treatment by Cyclic AMP Response Element Binding Nuclear Transcription Factor.

Authors:  Francesca D'Auria; Lucia Centurione; Maria Antonietta Centurione; Antonio Angelini; Roberta Di Pietro
Journal:  Front Oncol       Date:  2017-05-05       Impact factor: 6.244

10.  Context Matters: Distinct Disease Outcomes as a Result of Crebbp Hemizygosity in Different Mouse Bone Marrow Compartments.

Authors:  Ting Zhou; Stephanie N Perez; Ziming Cheng; Marsha C Kinney; Madeleine E Lemieux; Linda M Scott; Vivienne I Rebel
Journal:  PLoS One       Date:  2016-07-18       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.